


IN THE CLAIMS

Please delete claims 1 - 28 without prejudice or disclaimer, and amend claims 29 and 30 as follows:

Claims 1 - 28 (canceled)

Claim 29. (currently amended) A method of using a reversible inhibitor of DPP-IV, comprising administering to a human patient suffering from a central nervous system disorder a pharmaceutically effective amount of the inhibitor, wherein the inhibitor is



wherein R is NH-R^I;

R^I is: C₁ - C₁₂ straight or branched chain alkyl;

C₃ - C₇ cycloalkyl;

CH₂- CH₂-NH-R^{II};

CH₂- CH₂-R^{III};

CH₂- CH₂-CHR^{IV}- R^{IV}; or

CH₂- CH₂-CH₂-R^V;

R^{II} is a pyridine ring optionally substituted in one or two positions with halo, trifluoromethyl, cyano or nitro; or a pyrimidine ring optionally substituted in one position with halo, **[trifluoromethyl] trifluoromethyl**, cyano or nitro;

R^{III} is a phenyl ring optionally substituted in one to three positions with halo or $C_1 - C_3$ alkoxy;

Each R^{IV} is independently a phenyl ring optionally substituted in one position with halo or $C_1 - C_3$ alkoxy; and


R^V is a 2-oxopyrrolidine group or a $C_2 - C_4$ alkoxy group.

R^{III} is a phenyl ring optionally substituted in one to three positions with halo or $C_1 - C_3$ alkoxy;

Each R^{IV} is independently a phenyl ring optionally substituted in one position with halo or $C_1 - C_3$ alkoxy; and

R^V is a 2-oxopyrrolidine group or a $C_2 - C_4$ alkoxy group.

30. (currently amended) A method of using a reversible inhibitor of DPP-IV, comprising administering to a human patient suffering from a central nervous system disorder a **[pharamceutically] pharmaceutically** effective amount of the inhibitor, wherein the inhibitor is



wherein R is $NH-R^I$;

R^I is: C₁ - C₁₂ straight or branched chain alkyl optionally substituted with hydroxy, acetyl, C₁ - C₃ alkoxy, or C₁ - C₃ hydroxyalkyl;

C₃ - C₁₂ cycloalkyl optionally substituted with hydroxyl, acetyl, C₁ - C₃ alkoxy, or C₁ - C₃ hydroxyalkyl;

adamantyl; indanyl; piperidyl optionally substituted with benzyl; pyrrolidine optionally substituted with benzyl; bicycloheptyl optionally substituted in one to three positions with methyl; phenyl optionally substituted with in one to three positions with halo, methoxy, trifluoromethyl; pyridyl optionally substituted in one to three positions with halo, trifluoromethyl, nitro; or pyrimidyl optionally substituted with halo, trifluoromethyl, nitro;

C₁ - C₃ straight or branched chain alkyl substituted with R^{IV}, and optionally substituted with hydroxy; or

(CH₂)₁₋₃ - NR^{II}R^{III};

R^{II} is hydrogen or methyl;

R^{III} is phenyl optionally substituted with CN, or pyridyl optionally substituted with CN; and

R^{IV} is a group selected from phenyl, naphthyl, cyclohexenyl, pyridyl, pyrimidyl, adamantyl, phenoxy, wherein the group is optionally substituted in one to two positions with ethoxy, methoxy, halo, phenylsulfide, or phenylsulfide substituted with hydroxymethyl.